Latest Market Access News

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

archTIS Limited reported a 38% revenue decline and an 11.8% rise in net loss for FY2025, yet achieved positive operating cash flow and secured $7.5 million in new capital to accelerate international expansion.

NIMY Resources is set to release its maiden JORC Inferred Resource for gallium at the Mons Project in Western Australia, amid promising copper exploration results and strategic US market partnerships.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Gateway Mining Limited's trading suspension has been lifted following the release of new exploration results from its Yandal Gold Project, reopening market access for investors.

Omega Oil and Gas confirms the commercial viability of its Canyon Sandstone reservoir in Queensland’s Taroom Trough, with SLB modelling indicating nearly 1 million barrels of oil equivalent per well and significant upside potential.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Unibail-Rodamco-Westfield has requested suspension of its securities from the ASX, marking the first step toward its official delisting. This move signals a significant shift for investors and the commercial property sector.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.